Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipoplatin + verteporfin
- Development stage
- Phase 1
- Lead developer
- Regulon
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Lipoplatin + verteporfin is a combination therapy regimen investigated by the Centre Hospitalier Universitaire Vaudois (CHUV) for the treatment of malignant pleural effusion (MPE). The treatment consists of Lipoplatin, a liposomal nanoparticle formulation of the platinum-based alkylating agent cisplatin, administered intravenously in conjunction with Visudyne (verteporfin), a benzoporphyrin-derived photosensitizer. The therapeutic approach utilizes low-dose intrapleural photodynamic therapy (PDT), also termed photo-induction, to modulate the tumor microvasculature and enhance the localized uptake of systemically administered Lipoplatin into pleural malignancies. Cisplatin exerts its cytotoxic effect by forming intra-strand and inter-strand DNA crosslinks, which inhibit DNA replication and transcription, leading to cell cycle arrest and apoptosis. Verteporfin-mediated PDT is intended to overcome chemo-resistance and improve local tumor control in patients undergoing video-assisted thoracoscopic surgery (VATS) pleurodesis.
- Other names
- liposomal cisplatin + verteporfinLipoplatin + Visudyneliposomal cisplatin + Visudyne
02
Targets
TEAD1DNAYAP1 (YES-associated protein–transcriptional enhancer factor domain complex)
Beyond the preview
Go deeper on Lipoplatin + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lipoplatin + verteporfin.